Clinical trials: Adolescent HPV Vaccine
Neoplasms, Glandular and Epithelial, Diphtheria
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Data from this study are expected to demonstrate that V501 (Human Papillomavirus (HPV) [Types 6, 11, 16, 18] Recombinant Vaccine) , when administered concomitantly with a combined diphtheria, tetanus, pertussis (Tdap) vaccine and…
- Conditions
- Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough
- Trial name
- NCT00325130
- Testing
- Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine, Comparator: Menactra™ (Concomitant), Comparator: Adacel™ (Concomitant)
- Volunteers
- 1,042 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Human papillomavirus (HPV) infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV vaccine (580299) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18)…
- Trial name
- NCT00492544
- Testing
- Cervarix™ (HPV-16/18 L1 VLP AS04)
- Where
- 5 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Patient Compliance
Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study
There has been very limited research that has looked at electronic reminders (text messages) and its effectiveness in adherence to vaccination among low-income minority populations.
- Trial name
- NCT01908517
- Testing
- HPV Vaccine Electronic Reminders
- Where
- 2 sites in United States
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- East Carolina University
HPV Vaccine
HPV Ends Here: Increasing Uptake of the HPV Vaccine
Develop, implement, and evaluate a culturally tailored multilevel intervention to increase uptake of the HPV vaccine among eligible patients ages 10-12 of the University of California, Davis Health Community Physician (UCDH CP)…
- Trial name
- HPV (NCT06831929)
- Testing
- Intervention Arm
- Where
- United States
- Volunteers
- 2,232 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Healthy, Adolescents
Integration to Improve Adolescent Health and HPV Vaccination in Laos
The goal of this study is to find out if adding HPV vaccination to adolescent health services works to increase HPV vaccine uptake in 10-13-year-old girls in Laos.
- Conditions
- Healthy, Adolescents, Integrated, Community-Health Systems, HPV Vaccines
- Trial name
- NCT06650956
- Testing
- Integrated HPV and SRH Service Package, Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
- Where
- Laos
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Health Poverty Action
Meningococcal Meningitis
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
The main objective is to determine whether immune responses to Tdap (GlaxoSmithKline, Boostrix®) and HPV vaccine (Merck \& Co., Inc., Gardasil®) when administered concomitantly with MenACWY are comparable to responses elicited by…
- Trial name
- NCT01424644
- Testing
- MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
- Where
- 20 sites in United States, Italy
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- Novartis
Primary Prevention
Engaging Practices and Communities in the Development of Interventions to Promote HPV Vaccine Uptake
The overarching goal of this project is to implement Boot Camp Translation (BCT) methodology to translate the guidelines and evidence for human papillomavirus (HPV) vaccine into a practice and provider level intervention designed…
- Trial name
- NCT04279964
- Testing
- Boot Camp Translation, Control
- Where
- United States
- Volunteers
- 2,400 people
- Sponsor
- University of Colorado, Denver
Human Papillomavirus Infection
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers
Using health behavior theories and theories related to the effects of persuasive messages (i.e., inoculation theory), we plan to: 1.
- Trial name
- NCT01087164
- Testing
- Compliance, Message sidedness
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Indiana University
Neoplasms, Glandular and Epithelial, Diphtheria
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
Data from this study are expected to demonstrate that Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine), when administered concomitantly with a combined diphtheria, tetanus, pertussis, and…
- Conditions
- Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough
- Trial name
- NCT00337428
- Testing
- Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF), Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF), Comparator: REPEVAX™ (Concomitant)
- Volunteers
- 843 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus, Cervical Cancer
Survey of Predictors of Human Papillomavirus (HPV) Vaccination Among Parents of Rural Adolescent Girls in Mysore, India
To conduct a quantitative survey to measure knowledge about Human papillomavirus (HPV) and cervical cancer, and HPV vaccine acceptability among parents of rural adolescent girls in Mysore District, India.
- Trial name
- NCT01307774
- Where
- 2 sites in India
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Purnima Madhivanan
HPV16 Anitbody Levels Post Vaccination, HPV18 Antibody Levels Post Vaccination
HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda
Background: Cervical cancer is one of the leading causes of cancer death in women worldwide and in Uganda. It is caused by the human papillomavirus (HPV).
- Trial name
- NCT01520272
- Where
- Uganda
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
Background: Human papilloma virus (HPV) is a common sexually transmitted disease. There are more than 100 different HPV types, and both males and females can get HPV infection.
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
- Trial name
- NCT00798265
- Testing
- Gardasil, Survey
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Vaccines
HPV Centralized R/R RCT #2 - New York State
The work done in this trial builds off of the work previously conducted by this same research group in clinicaltrials.gov ID: NCT03057379.
- Trial name
- NCT03294551
- Testing
- HPV Vaccine Reminder Recall - Autodialer, HPV Vaccine Reminder Recall - Texting
- Where
- United States
- Volunteers
- 37,003 people
- Sponsor
- University of California, Los Angeles
HPV Vaccination, Uptake Vaccination
PREVENT HPV -Related Cancers Trial
This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West.
- Conditions
- HPV Vaccination, Uptake Vaccination, Series Completion
- Trial name
- NCT07217145
- Testing
- PREVENT
- Where
- United States
- Volunteers
- 1,455 people, healthy volunteers welcome
- Sponsor
- University of Utah
Infections, Papillomavirus
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
The purpose of this study is to establish the long-term persistence of the immune response and safety of the HPV vaccine in healthy females who were aged 9 to 25 years in the primary study (NCT00541970).
- Trial name
- NCT02100618
- Testing
- Blood sampling
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hpv
Effectiveness of HPV Vaccine Among Adolescents and Reproductive Women
To assess the effectiveness of HPV vaccine 2 doses or less to prevent HPV high risk infection among adolescents and adults. We conduct the test-negative control study including 12-45 women who interest to do a check-up pap smear.
- Trial name
- NCT06220747
- Where
- 2 sites in Thailand
- Volunteers
- 760 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Evaluating Attitudes Toward HPV Vaccinations in Pharmacies, Evaluating the Provision of HPV Vaccines in a Pharmacy
Adolescent Vaccination in Pharmacies
The study aims to expand the evidence supporting pharmacy provision of adolescent vaccines, including human papillomavirus (HPV) vaccine.
- Trial name
- AVIP (NCT01960088)
- Testing
- HPV vaccine
- Where
- 2 sites in United States
- Volunteers
- 1,509 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Human Papilloma Virus, Male
A Pilot Study Comparing the Effectiveness of Campus Intervention to Increase HPV Vaccine Rate Among College Aged Men
This is a study testing what type of message and access influences a young male to get the HPV vaccine. The investigators are conducting a 2 X 2 design These conditions are: Condition 1: Altruistic personal with direct…
- Trial name
- NCT02508701
- Testing
- Message X Onsite/Offsite Vaccination
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Purdue University
Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated Carcinoma
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
This vaccine was jointly developed by Chengdu Institute of Biological Products Co., Ltd. and National Vaccine and Serum Institute, China, is co-sponsoring this clinical trial.
- Trial name
- NCT06632912
- Testing
- 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha), 3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
- Where
- 3 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
HPV Infection, HPV Vaccination
Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
The risk for Human Papillomavirus (HPV) infection persists through an individual sexual life and duration of protection is critical to vaccine effectiveness in protection from oncogenic hrHPV infection.
- Trial name
- NCT05435209
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Where
- Kenya
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- University of Washington